source
- Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckleyEli Lilly said on Thursday it will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, in a move that further spotlights big pharma’s increasing interest in the space after years o…Endpoints · 15d ago↗ source
- Updated: Merck beats AstraZeneca to approval for first PCSK9 pillAs in football, so in pharmaceuticals: The English have been beaten. Merck has outpaced AstraZeneca in the race to get the first US approval for an oral form of a particular kind of cholesterol-low…Endpoints · 15d ago↗ source
- Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharmaTakeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac.